ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial
LOS ANGELES, Calif., April 2, 2020 (SEND2PRESS NEWSWIRE) — ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients. 